医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

バイオテクノロジー

EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor

EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for EMB-02, a Bispecific Dual Checkpoint Inhibitor

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬　 TimeLine: a Bispecific Dual Checkpoint Inhibitor EMB-02 EpimAb Biotherapeutics Announces FDA Clearance of its IND Application for

2020年09月15日

Genomic Leaders Collaborate to Create Australia’s First National COVID-19 Tracking System

バイオテクノロジーヘルスケア医療機器感染症遺伝学　 TimeLine: Genomic Leaders Collaborate to Create Australia’s First National COVID Tracking System

2020年09月15日

Shionogi Launches FETCROJA® (cefiderocol) in the United Kingdom for the Treatment of Infections Due to Aerobic Gram-Negative Bacteria in Adults With Limited Treatment Options

バイオテクノロジーヘルスケア感染症製薬　 TimeLine: cefiderocol FETCROJA Shionogi Launches

2020年09月15日

Vaxess Technologies to Develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen

Vaxess Technologies to Develop Coronavirus + Influenza Combo Patch Vaccine in Partnership with Medigen

その他ヘルスバイオテクノロジーヘルスケアヘルス一般感染症臨床試験製薬　 TimeLine: Influenza Combo Patch Vaccine in Partnership with Medigen Vaxess Technologies to Develop Coronavirus

2020年09月15日

Guided Therapeutics Ships LuViva Devices and Disposables for Chinese FDA Pivotal Clinical Trial

Guided Therapeutics Ships LuViva Devices and Disposables for Chinese FDA Pivotal Clinical Trial

その他ヘルスバイオテクノロジーヘルスケアヘルス一般医療機器医療用品病院腫瘍学臨床試験　 TimeLine: Guided Therapeutics Ships LuViva Devices and Disposables for Chinese FDA Pivotal Clinical Trial

2020年09月14日

Starpharma’s SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

Starpharma’s SPL7013 COVID-19 Nasal Spray Virucidal Against SARS-CoV-2

バイオテクノロジーヘルスケアヘルス一般感染症製薬　 TimeLine: Nasal Spray Virucidal Against SARS-CoV-2 Starpharma’s SPL7013 COVID

2020年09月14日

Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer

Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer

バイオテクノロジーヘルスケア腫瘍学臨床試験製薬　 TimeLine: Daiichi Sankyo Initiates Phase Study of Patritumab Deruxtecan in Patients with HER3 Expressing Advanced Colorectal Cancer

2020年09月14日

HiFiBiO Therapeutics Announces a Global Strategic Partnership With ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody

その他ヘルスバイオテクノロジーヘルスケアヘルス一般感染症腫瘍学臨床試験製薬　 TimeLine: ABL Bio for the Co-Development of a SARS-CoV-2 Neutralizing Antibody HiFiBiO Therapeutics Announces a Global Strategic Partnership With

2020年09月14日

TransEnterix Announces Establishment of Japanese Training Center for Senhance Surgical System

TransEnterix Announces Establishment of Japanese Training Center for Senhance Surgical System

バイオテクノロジーヘルスケア医療機器外科病院　 TimeLine: TransEnterix Announces Establishment of Japanese Training Center for Senhance Surgical System

2020年09月14日

Additional Analytical Results of the US-Based Phase 2b Clinical Trial of Regenerative Cell Medicine SB623 for the Treatment of Chronic Motor Deficit From Ischemic Stroke, and Review of Development Plans Based on These Results

Additional Analytical Results of the US-Based Phase 2b Clinical Trial of Regenerative Cell Medicine SB623 for the Treatment of Chronic Motor Deficit From Ischemic Stroke, and Review of Development Plans Based on These Results

バイオテクノロジーヘルスケア臨床試験製薬　 TimeLine: Additional Analytical Results and Review Development Plans Based on These Results US-Based Phase 2b Clinical Trial of Regenerative Cell Medicine SB623 for the Treatment of Chronic Motor Deficit From Ischemic Stroke

2020年09月14日